Asset profile

Levetiracetam (Keppra) · Keppra

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved — Epilepsy

Regulatory approval supersedes design-level evidence grading — the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

How the evidence outlook works ↗

Upcoming events

(9 total)

Estimated primary-completion dates from ClinicalTrials.gov — registry estimates, never confirmed readout dates; they can move as trials progress.

2027 (4)
January 2027 (1)
Phase 3EpilepsyRecruiting
Est. primary completion 2027-01 · NCT07239115 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

July 2027 (1)
Phase 2Neonatal Seizure, Neonatal Encephalopathy, Hypoxic-Ischemic Encephalopathy, Seizure NewbornRecruiting
Est. primary completion 2027-07-01 · NCT05610085 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

December 2027 (2)
Phase 2Hippocampal Hyperactivation, Prodromal Alzheimer DiseaseRecruiting
Est. primary completion 2027-12 · NCT07477431 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 3EpilepsyRecruiting
Est. primary completion 2027-12 · NCT07234695 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2028 (1)
December 2028 (1)
Phase 3EpilepsyRecruiting
Est. primary completion 2028-12-30 · NCT07490769 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2029 (2)
February 2029 (1)
Phase 2EpilepsyRecruiting
Est. primary completion 2029-02 · NCT07130786 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

June 2029 (1)
Phase 3EpilepsyRecruiting
Est. primary completion 2029-06 · NCT06907173 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2031 (1)
June 2031 (1)
Phase 3EpilepsyRecruiting
Est. primary completion 2031-06-01 · NCT06442748 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2033 (1)
December 2033 (1)
Phase 3Severe Preeclampsia, Eclampsia PreeclampsiaNot yet recruiting
Est. primary completion 2033-12-31 · NCT07220902 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

See the full readout calendar ↗

All registered studies

Research

Unlock the complete ClinicalTrials.gov registry

Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.

Competitive landscape

Research

Unlock the competitor landscape

Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.